[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SYTL4

Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Peripheral membrane protein Cell membrane Peripheral membrane protein Cytoplasmic vesicle, secretory vesicle membrane Peripheral membrane protein Note=Detected close to the plasma membrane and on secretory granules. In pancreas, interacts with insulin-containing vesicles (By similarity).
Domain PF00168 C2 domain
Function

Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner (By similarity).

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002792 negative regulation of peptide secretion
GO:0006836 neurotransmitter transport
GO:0006887 exocytosis
GO:0006906 vesicle fusion
GO:0007269 neurotransmitter secretion
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0016050 vesicle organization
GO:0016079 synaptic vesicle exocytosis
GO:0017156 calcium ion regulated exocytosis
GO:0017157 regulation of exocytosis
GO:0017158 regulation of calcium ion-dependent exocytosis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0042886 amide transport
GO:0044801 single-organism membrane fusion
GO:0045055 regulated exocytosis
GO:0045921 positive regulation of exocytosis
GO:0046676 negative regulation of insulin secretion
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0048284 organelle fusion
GO:0048489 synaptic vesicle transport
GO:0048791 calcium ion-regulated exocytosis of neurotransmitter
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0060627 regulation of vesicle-mediated transport
GO:0061025 membrane fusion
GO:0071985 multivesicular body sorting pathway
GO:0090087 regulation of peptide transport
GO:0090174 organelle membrane fusion
GO:0090276 regulation of peptide hormone secretion
GO:0090278 negative regulation of peptide hormone secretion
GO:0097479 synaptic vesicle localization
GO:0097480 establishment of synaptic vesicle localization
GO:0099003 vesicle-mediated transport in synapse
GO:0099504 synaptic vesicle cycle
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
GO:1903305 regulation of regulated secretory pathway
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0000149 SNARE binding
GO:0005543 phospholipid binding
GO:0005544 calcium-dependent phospholipid binding
GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0019905 syntaxin binding
GO:0030276 clathrin binding
GO:0031267 small GTPase binding
GO:0042043 neurexin family protein binding
GO:0051020 GTPase binding
Cellular Component GO:0005813 centrosome
GO:0019898 extrinsic component of membrane
GO:0030133 transport vesicle
GO:0030141 secretory granule
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0070382 exocytic vesicle
GO:0098793 presynapse
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SYTL4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SYTL4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SYTL4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5520.169
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1240.16
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1270.836
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1080.716
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3070.882
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1380.956
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9880.0756
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9670.311
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.0540.295
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.7870.0249
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6270.0338
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.020.884
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SYTL4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYTL4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYTL4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYTL4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYTL4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SYTL4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SYTL4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSYTL4
Namesynaptotagmin-like 4
Aliases granuphilin-a; exophilin-2; Granuphilin; Synaptotagmin-like protein 4
Chromosomal LocationXq21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SYTL4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SYTL4.
ID Name Drug Type Targets #Targets
DB00030Insulin HumanBiotechCPE, CTSD, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV, PCSK1, PCSK2, RB1, ......12
DB00071Insulin PorkBiotechCPE, CTSD, HLA-DQA2, HLA-DQB1, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV ......14